Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Sarawgi

What You Need to Know Ahead of Incyte's Earnings Release

Delaware-based Incyte Corporation (INCY) focuses on the discovery, development, and commercialization of therapeutics for hematology, oncology, and inflammation & autoimmunity conditions. Valued at nearly $14 billion by market cap, Incyte’s expertise in medicinal chemistry and biology has enabled it to create a diversified portfolio of marketed products and clinical candidates.

The biopharma major is expected to announce its fourth-quarter results on Tuesday, Feb. 11. Ahead of the event, analysts expect Incyte to report a profit of $1.34 per share, up by a staggering 63.4% from $0.82 per share reported in the year-ago quarter. However, the company has missed Wall Street’s bottom-line estimates in each of the past four quarters.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.